Pantoprazole Kleva 40 Mg

Pantoprazole, the active ingredient in Pantoprazole Kleva 40 Mg, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazole Kleva 40 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Pantoprazole Kleva 40 Mg is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare condition.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation: occasional. - Dry mouth.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile‑associated colitis: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Liver enzyme elevation: hepatitis‑like picture in rare cases.

Before initiating therapy, consider the following safety points: - Assess renal function: dose adjustment may be needed in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Monitor for long‑term use: evaluate need for calcium, vitamin D and bone health. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Elderly patients: start at the lowest effective dose and monitor for adverse effects. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption and loss of efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): markedly decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate: reduced renal clearance may raise toxicity risk. - Digoxin: slight increase in serum levels; observe for signs of toxicity.